Document and Entity Information
Document and Entity Information | Nov. 08, 2023 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001628171 |
Document Type | 8-K/A |
Document Period End Date | Nov. 08, 2023 |
Entity Registrant Name | Revolution Medicines, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-39219 |
Entity Tax Identification Number | 47-2029180 |
Entity Address, Address Line One | 700 Saginaw Drive |
Entity Address, City or Town | Redwood City |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94063 |
City Area Code | 650 |
Local Phone Number | 481-6801 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.0001 par value per share |
Trading Symbol | RVMD |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Amendment No. 1 to Current Report on Form 8-K/A is being filed with the Securities and Exchange Commission solely to amend and supplement Item 9.01 of the Current Report on Form 8-K (the “Original 8-K”) filed by Revolution Medicines, Inc., a Delaware corporation (“Revolution Medicines”), on November 9, 2023, reporting under Item 2.01 the completion of its previously announced acquisition (the “Acquisition”) of EQRx, Inc., a Delaware corporation (“EQRx”). Under Item 9.01 of the Original 8-K, Revolution Medicines stated that pro forma financial statements would be filed by amendment no later than 71 days following the date that the Original 8-K was required to be filed. No other changes have been made to the Original 8-K. |